2012
Patterns and Loss of Sexual Activity in the Year Following Hospitalization for Acute Myocardial Infarction (a United States National Multisite Observational Study)
Lindau ST, Abramsohn E, Gosch K, Wroblewski K, Spatz ES, Chan PS, Spertus J, Krumholz HM. Patterns and Loss of Sexual Activity in the Year Following Hospitalization for Acute Myocardial Infarction (a United States National Multisite Observational Study). The American Journal Of Cardiology 2012, 109: 1439-1444. PMID: 22546209, PMCID: PMC3341956, DOI: 10.1016/j.amjcard.2012.01.355.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionActivity 1 yearSexual activityMyocardial infarctionMain outcome measurementsActivity-related outcomesThird of womenMultivariable hierarchical modelsHospital discharge instructionsLack of counselingMultisite observational studyCorrelates of lossTRIUMPH registryPhysician counselingDischarge counselingYear mortalityDischarge instructionsMean ageObservational studyOutcome measurementsHospitalizationFirst monthPatientsMortalityInfarction
2011
Effect of Living Alone on Patient Outcomes After Hospitalization for Acute Myocardial Infarction
Bucholz EM, Rathore SS, Gosch K, Schoenfeld A, Jones PG, Buchanan DM, Spertus JA, Krumholz HM. Effect of Living Alone on Patient Outcomes After Hospitalization for Acute Myocardial Infarction. The American Journal Of Cardiology 2011, 108: 943-948. PMID: 21798499, PMCID: PMC3670597, DOI: 10.1016/j.amjcard.2011.05.023.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionSeattle Angina QuestionnaireMyocardial infarctionPatient outcomesLife 1 yearRegistry of patientsHealth status measurementPhysical health componentAngina QuestionnaireMultivariable adjustmentLife scoresTreatment characteristicsComparable riskOutcome measurementsPatientsReadmissionHealth componentHealth statusMean qualityMortalityStatus measurementsComponent scaleOutcomesInfarctionSocial support
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2007
Measuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement
Krumholz HM, Normand SL, Spertus JA, Shahian DM, Bradley EH. Measuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement. Health Affairs 2007, 26: 75-85. PMID: 17211016, DOI: 10.1377/hlthaff.26.1.75.Peer-Reviewed Original Research